Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

During the last decade, the use of tyrosine kinase inhibitor (TKI) therapy has modified the natural history of chronic myeloid leukemia (CML) allowing an increase of the overall and disease-free survival, especially in patients in whom molecular residual disease becomes undetectable. However, it has...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Oncotarget
Główni autorzy: Chomel, Jean Claude, Bonnet, Marie Laure, Sorel, Nathalie, Sloma, Ivan, Bennaceur-Griscelli, Annelise, Rea, Delphine, Legros, Laurence, Marfaing-Koka, Anne, Bourhis, Jean-Henri, Ame, Shanti, Guerci-Bresler, Agnès, Rousselot, Philippe, Turhan, Ali G.
Format: Artigo
Język:Inglês
Wydane: Impact Journals LLC 2016
Hasła przedmiotowe:
Research Paper
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085229/
https://ncbi.nlm.nih.gov/pubmed/27167108
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9182
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy